Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance
Authors:
- Li WangLWLi Wang
- Jie MaJMJie Ma
- FengHua LiuFLFengHua Liu
- QingKai YuQYQingKai Yu
- GuangMin ChuGCGuangMin Chu
- Alan C. PerkinsAPAlan C. Perkins
- Yong LiYong Li
- 1 June 2007
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 105 (3) , 695-702
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypothesesMolecular and Cellular Endocrinology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Ovarian Cancer Metastasis: Integrating insights from disparate model organismsNature Reviews Cancer, 2005
- Mucins in cancer: protection and control of the cell surfaceNature Reviews Cancer, 2004
- Reproductive and dietary risk factors for epithelial ovarian cancer in ChinaGynecologic Oncology, 2004
- Current research and treatment for epithelial ovarian cancer A Position Paper from the Helene Harris Memorial TrustEuropean Journal of Cancer, 2003
- Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: A retrospective case-control studyInternational Journal of Gynecological Cancer, 2003
- Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology GroupJournal of Clinical Oncology, 2003
- MUC1 Mucin Expression in Transitional Cell Carcinoma of the Bladder: A Target Antigen for Diagnosis and Therapy with Monoclonal Antibody C595Journal of Urologic Pathology, 2000
- C595 – a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomasBritish Journal of Cancer, 1990